Why the Therapeutic Impact of RAS Mutation Clearance in Plasma ctDNA Deserves to Be Further Explored in Metastatic Colorectal Cancer
Front Oncol
.
2019 Dec 17:9:1414.
doi: 10.3389/fonc.2019.01414.
eCollection 2019.
Authors
Chiara Nicolazzo
1
,
Francesca Belardinilli
2
,
Salvatore Caponnetto
3
,
Angela Gradilone
1
,
Enrico Cortesi
3
,
Giuseppe Giannini
2
4
,
Paola Gazzaniga
1
Affiliations
1
Liquid Biopsy Unit, Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
2
Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
3
Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Rome, Italy.
4
Institute Pasteur-Cenci Bolognetti Foundation, Rome, Italy.
PMID:
31921671
PMCID:
PMC6933952
DOI:
10.3389/fonc.2019.01414
No abstract available
Keywords:
EGFR inhibitiors; RAS; colorectal cancer; ctDNA; liquid biopsy.